Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Long-Term Efficacy of a 6-Month Regimen of Rituximab and Lenalidomide in Follicular Lymphoma Patients in Need of First Therapy: Updated Analysis of the SAKK 35/10 Randomized Trial

Blood (2023) 142 (Supplement 1): 295.

https://doi.org/10.1182/blood-2023-173957

Published: 2023

Journal Articles

Long-Term Follow-up of Clinical Outcome Determinants and Correlative Biological Features from the Nordic NLG-T-01 Trial

Blood (2022) 140 (Supplement 1): 1479–1480.

https://doi.org/10.1182/blood-2022-158981

Published: 2022

Journal Articles

Diversity of Intratumoral Regulatory T Cells in Non-Hodgkin Lymphoma

Blood (2021) 138 (Supplement 1): 3519.

https://doi.org/10.1182/blood-2021-152801

Published: 2021

Journal Articles

Heterogeneity of Regulatory T Cells in B-Cell Non-Hodgkin Lymphoma

Ivana Spasevska, Sarah Josefsson, PhD MSc, Yngvild Nuvin Blaker, MD PhD, Chloe B. Steen, PhD, Ankush Sharma, PhD, Kushi Kushekhar, PhD MSc, Saskia Meyer, PhD, Arne Kolstad, MD PhD, Klaus Beiske, MD PhD, Harald Holte, MD PhD, Bjørn Østenstad, MD PhD, Eva Kimby, MD PhD, Johanna Olweus, PhD, Kjetil Tasken, PhD, Suzanne Lorenz, PhD, Erlend B. Smeland, PhD MD, Ash A. Alizadeh, MD PhD, Kanutte Huse, PhD, June Helen Myklebust, PhD

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-142380

Published: 2020

Journal Articles

Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy

Blood (2019) 134 (4): 353–362.

https://doi.org/10.1182/blood-2018-10-879643

Published: 2019

Includes: Supplemental data

Journal Articles

M7-FLIPI Not Valid in Follicular Lymphoma Patients with First-Line Rituximab Chemo-Free Therapy

Sandra Lockmer, MD, Weicheng Ren, PhD, Bjorn Ostenstad, MD PhD, Marianne Brodtkorb, MD PhD, Björn E Wahlin, Qiang Pan-Hammarstrom, MD PhD, Eva Kimby, MD PhD

Blood (2018) 132 (Supplement 1): 4154.

https://doi.org/10.1182/blood-2018-99-117949

Published: 2018

Journal Articles

The PRIMA-Prognostic Index (PI) Is Valid in Follicular Lymphoma (FL) Patients with Rituximab Chemo-Free First-Line Treatment

Eva Kimby, MD PhD, Sandra Lockmer, MD, Harald Holte, MD PhD, Björn E Wahlin, Hans Hagberg, MD, Peter De Nully Brown, Björn Östenstad, MD

Blood (2018) 132 (Supplement 1): 4150.

https://doi.org/10.1182/blood-2018-99-114866

Published: 2018

Journal Articles

Long-Term Follow-up of Patients with Indolent Lymphoma after First Line Therapy with Rituximab As Single Agent or in Combination with Interferon-α2a

Sandra Lockmer, Bjorn Ostenstad, Hans Hagberg, Harald Holte, Björn Engelbrekt Wahlin, Chloe Beate Steen, Peter de Nully Brown, MD PhD, Eva Kimby

Blood (2017) 130 (Supplement 1): 2768.

https://doi.org/10.1182/blood.V130.Suppl_1.2768.2768

Published: 2017

Journal Articles

Combined Clinical and Gene Expression Score Identifies Follicular Lymphoma Patients with High Risk of Transformation in the Rituximab Era

Chloe Beate Steen, Ellen Leich, June Helen Myklebust, PhD, Sandra Lockmer, Jillian Frances Wise, Björn Engelbrekt Wahlin, Bjørn Østenstad, Knut Liestol, Eva Kimby, Andreas Rosenwald, Erlend Bremertun Smeland, Harald Holte, Ole Christian Lingjærde, Marianne Brodtkorb

Blood (2017) 130 (Supplement 1): 1467.

https://doi.org/10.1182/blood.V130.Suppl_1.1467.1467

Published: 2017

Journal Articles

Rituximab Plus Lenalidomide Versus Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. First Analysis of Survival Endpoints of the Randomized Phase-2 Trial SAKK 35/10

Blood (2016) 128 (22): 1099.

https://doi.org/10.1182/blood.V128.22.1099.1099

Published: 2016

Journal Articles

Immune Cell Dynamics in Nordic FL Patients in the SAKK 35/10 Randomized Trial with Rituximab and Lenalidomide

Sandra Lockmer, MD, Björn E Wahlin, MD PhD, Bjorn Ostenstad, MD PhD, Åsa Jeppson-Ahlberg, Birgitta Sander, MD PhD, Eva Kimby, MD PhD

Blood (2016) 128 (22): 5338.

https://doi.org/10.1182/blood.V128.22.5338.5338

Published: 2016

Journal Articles

Identification of Tigit on Intra-Tumor T Cells As a New Target for Immune Checkpoint Blockade in Follicular Lymphoma

Sarah Gothberg, Kanutte Huse, Arne Kolstad, MD PhD, Ole Christian Lingjærde, PhD, Bjørn Østenstad, MD PhD, Erlend Smeland, MD PhD, Ronald Levy, MD, Jonathan Michael Irish, PhD, June Helen Myklebust, PhD

Blood (2016) 128 (22): 917.

https://doi.org/10.1182/blood.V128.22.917.917

Published: 2016

Journal Articles

Sequential Immune Cell Modulation in Nordic Follicular Lymphoma Patients in the SAKK 35/10 Randomized Trial with Rituximab and Lenalidomide

Sandra Lockmer, MD PhDstud, Björn E Wahlin, MD PhD, Bjorn Ostenstad, MD PhD, Åsa Jeppson-Ahlberg, Birgitta Sander, MD PhD, Eva Kimby, MD PhD

Blood (2015) 126 (23): 1535.

https://doi.org/10.1182/blood.V126.23.1535.1535

Published: 2015

Journal Articles

Rituximab Plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. Primary Endpoint Analysis of the Randomized Phase-2 Trial SAKK 35/10

Blood (2014) 124 (21): 799.

https://doi.org/10.1182/blood.V124.21.799.799

Published: 2014

Journal Articles

Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment

Olav Erich Yri, Dag Torfoss, Olav Hungnes, Anne Tierens, Kristian Waalen, Tone Nordøy, Susanne Dudman, Anette Kilander, Karin Fahl Wader, Bjørn Østenstad, Roald Ekanger, Peter Meyer, Arne Kolstad

Blood (2011) 118 (26): 6769–6771.

https://doi.org/10.1182/blood-2011-08-372649

Published: 2011

Journal Articles

High-Dose Chemotherapy and Autologuos Stem Cell Transplantation in Previously Untreated Peripheral T-Cell Lymphoma - Final Analysis of a Large Prospective Multicenter Study (NLG-T-01)

Blood (2011) 118 (21): 331.

https://doi.org/10.1182/blood.V118.21.331.331

Published: 2011

Journal Articles

Increasing Grades of Follicular Lymphoma Correlate with Better Prognosis in Patients Treated with Rituximab

Björn Engelbrekt Wahlin, MD, PhD, Christer Sundström, Harald Holte, Birgitta Sander, MD, Ph.D., Bjørn Østenstad, Peter de Nully Brown, Erlend B. Smeland, Jan Delabie, Birger Christensson, M.D., Ph.D., Eva Kimby, M.D., Ph.D.

Blood (2011) 118 (21): 1641.

https://doi.org/10.1182/blood.V118.21.1641.1641

Published: 2011

Journal Articles

Age-Adjusted Combined Immunochemotherapy without Radiotherapy in Newly Diagnosed PCNSL – A Phase II Trial of the Nordic Lymphoma Group

Elisa Jacobsen Pulczynski, Peter Kamper, Unn-Merete Fagerli, Martin Erlanson, Outi Kuittinen, Alexander Fosså, Bjørn Østenstad, Oystein Fluge, Martin Maisenhølder, Hans Hagberg, Mikael Eriksson, Marie Nordstrøm, Sirpa Leppa

Blood (2011) 118 (21): 1602.

https://doi.org/10.1182/blood.V118.21.1602.1602

Published: 2011

Journal Articles

Increased Bone Marrow Microvascular Density in Hematologic Malignancies

Helene Francisca Stigter Negaard, MD, Nina Iversen, PhD, Inger Marie Bowitz-Lothe, MD, Per Morten Sandset, MD, PhD, Brit Steinsvik, Bjørn Østenstad, MD, PhD, Per Ole Iversen, MD, PhD

Blood (2008) 112 (11): 5456.

https://doi.org/10.1182/blood.V112.11.5456.5456

Published: 2008

NARROW

Long-Term Efficacy of a 6-Month Regimen of Rituximab and Lenalidomide in Follicular Lymphoma Patients in Need of First Therapy: Updated Analysis of the SAKK 35/10 Randomized Trial

Long-Term Follow-up of Clinical Outcome Determinants and Correlative Biological Features from the Nordic NLG-T-01 Trial

Diversity of Intratumoral Regulatory T Cells in Non-Hodgkin Lymphoma

Heterogeneity of Regulatory T Cells in B-Cell Non-Hodgkin Lymphoma

Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy

M7-FLIPI Not Valid in Follicular Lymphoma Patients with First-Line Rituximab Chemo-Free Therapy

The PRIMA-Prognostic Index (PI) Is Valid in Follicular Lymphoma (FL) Patients with Rituximab Chemo-Free First-Line Treatment

Long-Term Follow-up of Patients with Indolent Lymphoma after First Line Therapy with Rituximab As Single Agent or in Combination with Interferon-α2a

Combined Clinical and Gene Expression Score Identifies Follicular Lymphoma Patients with High Risk of Transformation in the Rituximab Era

Rituximab Plus Lenalidomide Versus Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. First Analysis of Survival Endpoints of the Randomized Phase-2 Trial SAKK 35/10

Immune Cell Dynamics in Nordic FL Patients in the SAKK 35/10 Randomized Trial with Rituximab and Lenalidomide

Identification of Tigit on Intra-Tumor T Cells As a New Target for Immune Checkpoint Blockade in Follicular Lymphoma

Sequential Immune Cell Modulation in Nordic Follicular Lymphoma Patients in the SAKK 35/10 Randomized Trial with Rituximab and Lenalidomide

Rituximab Plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. Primary Endpoint Analysis of the Randomized Phase-2 Trial SAKK 35/10

Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment

High-Dose Chemotherapy and Autologuos Stem Cell Transplantation in Previously Untreated Peripheral T-Cell Lymphoma - Final Analysis of a Large Prospective Multicenter Study (NLG-T-01)

Increasing Grades of Follicular Lymphoma Correlate with Better Prognosis in Patients Treated with Rituximab

Age-Adjusted Combined Immunochemotherapy without Radiotherapy in Newly Diagnosed PCNSL – A Phase II Trial of the Nordic Lymphoma Group

Increased Bone Marrow Microvascular Density in Hematologic Malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only